Why Eli Lilly’s CFO Sees Cancer Drugs as the Next Growth Drivers

Eli Lilly posts earnings that handily top estimates, fueled by strong performance in its metabolic portfolio. Continue Reading

阅读完整 Veytics 简报

我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。